Synuclein gamma compromise spindle assembly checkpoint and renders resistance to antimicrotubule drug

Suyu Miao,Kejin Wu,Bo Zhang,Ziyi Weng,Mingjie Zhu,Yunshu Lu,Ramadas Krishna,Yuenian Eric Shi
DOI: https://doi.org/10.1158/1535-7163.mct-13-0671
2013-01-01
Molecular Cancer Therapeutics
Abstract:Defects in the spindle assembly checkpoint (SAC) have been proposed to contribute to the chromosomal instability in human cancers. One of the major mechanisms underlying antimicrotubule drug (AMD) resistance involves acquired inactivation of SAC. Synuclein gamma (SNCG), previously identified as a breast cancer specific gene, is highly expressed in malignant cancer cells but not in normal epithelium. Here, we show that SNCG is sufficient to induce resistance to AMD-caused apoptosis in breast cancer cells and cancer xenografts. SNCG binds to spindle checkpoint kinase BubR1 and inhibits its kinase activity. Specifically, the C-terminal (Gln106-Asp127) of SNCG binds to the N-terminal TPR motif of BubR1. SNCG-BubR1 interaction induces a structure change of BubR1, attenuates its interaction with other key checkpoint protein of Cdc20, and thus compromise SAC function. SNCG expression in breast cancers from patients with a neoadjuvant clinical trial showed that SNCG-positive tumors are resistant to chemotherapyinduced apoptosis. These data show that SNCG renders AMD resistance by inhibiting BubR1 activity and attenuating SAC function. on June 21, 2017. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2014; DOI: 10.1158/1535-7163.MCT-13-0671
What problem does this paper attempt to address?